Overview

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This trial is to assess the efficacy of pembrolizumab added to concurrent chemotherapy with or without radiation therapy in patients with small cell lung cancer (SCLC).
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Carboplatin
Cisplatin
Etoposide
Etoposide phosphate
Pembrolizumab